CU20170128A7 - Compuestos de diazepina-indol sustituidos útiles en el tratamiento o la prevención del trastorno asociado con la actividad del receptor 1 de la hormona concentradora de la melanina - Google Patents

Compuestos de diazepina-indol sustituidos útiles en el tratamiento o la prevención del trastorno asociado con la actividad del receptor 1 de la hormona concentradora de la melanina

Info

Publication number
CU20170128A7
CU20170128A7 CUP2017000128A CU20170128A CU20170128A7 CU 20170128 A7 CU20170128 A7 CU 20170128A7 CU P2017000128 A CUP2017000128 A CU P2017000128A CU 20170128 A CU20170128 A CU 20170128A CU 20170128 A7 CU20170128 A7 CU 20170128A7
Authority
CU
Cuba
Prior art keywords
prevention
activity
treatment
disorders
concentrating hormone
Prior art date
Application number
CUP2017000128A
Other languages
English (en)
Other versions
CU24451B1 (es
Inventor
Gyula Beke
András Boros
János Éles
Sándor Farkas
György Miklós Keserü
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of CU20170128A7 publication Critical patent/CU20170128A7/es
Publication of CU24451B1 publication Critical patent/CU24451B1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

<p>La presente invención se relaciona con compuestos de diazepina-indol sustituidos de la fórmula general (I)</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>en donde el significado de A, R, R1, R2 y R3 se especifica en las reivindicaciones, y/o sales, y/o isómeros geométricos, y/o estereoisómeros, y/o diastereómeros, y/o hidratos, y/o solvatos, y/o modificaciones de polimorfos de los mismos, las composiciones farmacéuticas que los contienen y los nuevos intermediarios de estos, los cuales son útiles en el tratamiento o prevención de trastornos asociados con la actividad del receptor 1 de la hormona concentradora de la melanina, como la obesidad, condiciones y complicaciones comórbidas relacionadas con la obesidad, diabetes, trastornos metabólicos, enfermedades siquiátrico acompañadas de aumento de peso, enfermedades inflamatorias intestinales, disfunciones afectivas, trastornos de ansiedad, enfermedades del ciclo sueño-vigilia y trastornos de abuso y adicción de sustancias.</p>
CU2017000128A 2015-04-15 2016-04-14 Compuestos de diazepina-indol sustituidos útiles en el tratamiento o la prevención del trastorno asociado con la actividad del receptor 1 de la hormona concentradora de la melanina CU24451B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1500169A HU230880B1 (hu) 2015-04-15 2015-04-15 Indol származékok
PCT/IB2016/052110 WO2016166684A1 (en) 2015-04-15 2016-04-14 Indole derivatives

Publications (2)

Publication Number Publication Date
CU20170128A7 true CU20170128A7 (es) 2018-01-10
CU24451B1 CU24451B1 (es) 2019-11-04

Family

ID=89991787

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2017000128A CU24451B1 (es) 2015-04-15 2016-04-14 Compuestos de diazepina-indol sustituidos útiles en el tratamiento o la prevención del trastorno asociado con la actividad del receptor 1 de la hormona concentradora de la melanina

Country Status (34)

Country Link
US (1) US10329296B2 (es)
EP (1) EP3286193B1 (es)
JP (1) JP6783793B2 (es)
KR (1) KR102591750B1 (es)
CN (1) CN107466294B (es)
AR (1) AR104261A1 (es)
AU (1) AU2016248969B2 (es)
CA (1) CA2982232C (es)
CL (1) CL2017002605A1 (es)
CO (1) CO2017011511A2 (es)
CU (1) CU24451B1 (es)
CY (1) CY1123185T1 (es)
DK (1) DK3286193T3 (es)
EA (1) EA034427B1 (es)
ES (1) ES2804519T3 (es)
GE (1) GEP20207067B (es)
HR (1) HRP20201289T1 (es)
HU (2) HU230880B1 (es)
IL (1) IL254711B (es)
LT (1) LT3286193T (es)
MX (1) MX2017013201A (es)
MY (1) MY189372A (es)
PE (1) PE20180196A1 (es)
PH (1) PH12017501736B1 (es)
PL (1) PL3286193T3 (es)
PT (1) PT3286193T (es)
RS (1) RS60605B1 (es)
SA (1) SA517390161B1 (es)
SG (1) SG11201707772RA (es)
SI (1) SI3286193T1 (es)
TW (1) TWI703145B (es)
UA (1) UA121046C2 (es)
UY (1) UY36608A (es)
WO (1) WO2016166684A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére
HU231731B1 (hu) 2022-06-17 2026-01-28 Richter Gedeon Nyrt. 4-[(5-klór-piridin-2-il)metoxi]-1-[3-(propán-2-il)-1H,2H,3H,4H,5H-[1,4]diazepino [1,7-a]indol-9-il]-1,2-dihidropiridin-2-on kristályos formái és ezek sói, valamint előállításuk és alkalmazásuk
HUP2300374A1 (hu) 2023-11-03 2025-05-28 Richter Gedeon Nyrt 18F és 11C radioaktívan jelzett MCHR1 PET ligandumok

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU193083B (en) * 1984-02-22 1987-08-28 Sandoz Ag Process for preparing diazepinoindole derivatives further pharmaceutical compositions containing such compounds
AU2001243163B2 (en) 2000-03-14 2004-11-04 Pharmacia & Upjohn Company Novel 2,3,4,5-tetrahydro-1H-(1,4)diazepino(1,7a)indole compounds
JP2007502283A (ja) 2003-08-13 2007-02-08 アムジェン インコーポレイテッド メラニン凝集ホルモン受容体アンタゴニスト
EP1916239A4 (en) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd PYRIDOLVERBINDUNG
WO2008134480A1 (en) 2007-04-25 2008-11-06 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
WO2008140239A1 (en) 2007-05-11 2008-11-20 Korea Research Institute Of Chemical Technology Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
US8716308B2 (en) * 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
US20120083489A1 (en) * 2009-06-03 2012-04-05 Christensen Iv Siegfried Benjamin Bis-pyridylpyridones as melanin-concentrating hormone receptor antagonists
WO2011003005A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011127643A1 (en) 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. Pyridone derivatives
US20120316200A1 (en) 2010-04-12 2012-12-13 Merck Sharp & Dohme Corp. Pyridone derivatives
WO2012088124A2 (en) * 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
US8933079B2 (en) 2012-03-07 2015-01-13 Boehringer Ingelheim International Gmbh Pyridone and pyridazinone derivatives as anti-obesity agents
WO2013149362A1 (en) 2012-04-06 2013-10-10 Glaxosmithkline Llc 1-(dihydronaphthalenyl)pyridones as melanin-concentrating hormone receptor 1 antagonists
WO2014039411A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
US20140163012A1 (en) 2012-12-11 2014-06-12 Albany Molecular Research, Inc. Pyrido-/azepino-benzofuran and pyrido-/azepino-benzothiophene mch-1 antagonists, methods of making, and use thereof

Also Published As

Publication number Publication date
CY1123185T1 (el) 2021-10-29
JP6783793B2 (ja) 2020-11-11
TWI703145B (zh) 2020-09-01
WO2016166684A1 (en) 2016-10-20
CL2017002605A1 (es) 2018-03-16
PH12017501736B1 (en) 2022-07-22
EP3286193B1 (en) 2020-05-27
SI3286193T1 (sl) 2020-10-30
CA2982232A1 (en) 2016-10-20
DK3286193T3 (da) 2020-08-24
JP2018511637A (ja) 2018-04-26
UA121046C2 (uk) 2020-03-25
EA201792170A1 (ru) 2018-03-30
HUE16718017T2 (hu) 2021-03-29
UY36608A (es) 2016-09-30
AU2016248969B2 (en) 2020-03-12
AR104261A1 (es) 2017-07-05
NZ736551A (en) 2024-08-30
BR112017021843A2 (pt) 2018-07-10
PE20180196A1 (es) 2018-01-26
EA034427B1 (ru) 2020-02-06
IL254711A0 (en) 2017-11-30
HK1243705A1 (en) 2018-07-20
IL254711B (en) 2021-06-30
SA517390161B1 (ar) 2021-07-12
CO2017011511A2 (es) 2017-11-21
CA2982232C (en) 2023-03-28
CN107466294A (zh) 2017-12-12
PH12017501736A1 (en) 2018-03-12
KR20170137130A (ko) 2017-12-12
PT3286193T (pt) 2020-08-26
RS60605B1 (sr) 2020-08-31
EP3286193A1 (en) 2018-02-28
US10329296B2 (en) 2019-06-25
GEAP201914624A (es) 2019-10-10
TW201708226A (zh) 2017-03-01
MY189372A (en) 2022-02-08
ES2804519T3 (es) 2021-02-08
CN107466294B (zh) 2020-01-17
HUP1500169A2 (en) 2016-10-28
US20180093989A1 (en) 2018-04-05
HU230880B1 (hu) 2018-11-29
HRP20201289T1 (hr) 2020-11-13
CU24451B1 (es) 2019-11-04
SG11201707772RA (en) 2017-10-30
LT3286193T (lt) 2020-08-10
MX2017013201A (es) 2018-02-09
GEP20207067B (en) 2020-02-10
PL3286193T3 (pl) 2020-11-16
AU2016248969A1 (en) 2017-11-09
KR102591750B1 (ko) 2023-10-19

Similar Documents

Publication Publication Date Title
CO2020011908A2 (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CU20200067A7 (es) Derivados de imidazolidin-2-ona sustituidos como inhibidores de prmt5
CO2020000056A2 (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de la fibrosis
NI201000090A (es) Agonistas novedosos de los receptores de glucocorticoides.
ECSP16071151A (es) Inhibidores de dihidropirrolopiridina de ror-gamma
DOP2016000270A (es) Inhibidores espirocíclicos sustituidos de la autotaxina y su preparación y uso en el tratamiento de enfermedades dependientes o mediadas por lpa
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
CO2022003457A2 (es) Triazolopirimidinas como inhibidores de a2a/a2b
CL2016001790A1 (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2.
ECSP20024651A (es) Derivados de imidazol condensados sustituidos por grupos de hidroxilo terciario como inhibidores de gamma pi3k-y
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
CU24603B1 (es) Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios
CU24410B1 (es) Benzimidazol-2-aminas como inhibidores de midh1
CU20170144A7 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores gamma ror
CY1124381T1 (el) Παραγωγα οξαδιαζολοπυριδινης για χρηση ως αναστολεις της ο-ακυλο τρανσφερασης της γκρελινης
EA033250B1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
NI202000029A (es) Amidas de imidazopiridina sustituidas y su uso
CU20200038A7 (es) Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3
UY33231A (es) Aminotiazolonas como moduladores de los receptores de estrógenos alfa
MX2019003310A (es) Inhibidores de dopamina-b-hidroxilasa.
CU20170128A7 (es) Compuestos de diazepina-indol sustituidos útiles en el tratamiento o la prevención del trastorno asociado con la actividad del receptor 1 de la hormona concentradora de la melanina